Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.805
+0.1051.21%
Volume:55.66M
Turnover:489.54M
Market Cap:101.45B
PE:22.16
High:8.850
Open:8.820
Low:8.685
Close:8.700
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.45
T/O Rate:0.48%
Dividend:0.34
Dividend Rate:3.83%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.31
PE(LYR):22.16
PS:2.77

Loading ...

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Aug 26

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Aug 26

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

Reuters
·
Aug 26

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

Stock News
·
Aug 26

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 26

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Aug 26

Movement Alert|CSPC PHARMA Rises 3.13% in Regular Trading, RSV Vaccine Receives FDA Clinical Trial Approval While Multiple Banks Raise Target Prices

Market Focus
·
Aug 26

CSPC Pharma secures U.S. FDA clearance for Phase I trial of second recombinant RSV vaccine SYS6057

Bulletin Express
·
Aug 25

CSPC Pharma's Recombinant RSV Vaccine Wins US Clinical Trial Clearance

Stock News
·
Aug 25

CSPC Says FDA Clears RSV Vaccine Candidate SYS 6057 for US Clinical Trial

Reuters
·
Aug 25

CSPC Pharmaceutical - Recombinant Respiratory Syncytial Virus Vaccine (Sys6057) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Aug 25

CSPC Pharmaceutical - Sys6057 Receives Nmpa Approval on July 30, 2026 to Conduct Clinical Trials in China

THOMSON REUTERS
·
Aug 25

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live
·
Aug 24

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 24

Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results

Stock News
·
Aug 24

Movement Alert|CSPC PHARMA Rises 4.46% in Regular Trading, Multiple Investment Banks Raise Target Prices Post-Earnings

Market Focus
·
Aug 24

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

Deep News
·
Aug 23

UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating

Deep News
·
Aug 23